Trovafloxacin
Trovafloxacin is a topic covered in the Johns Hopkins ABX Guide.
To view the entire topic, please log in or purchase a subscription.
Pediatrics Central™ is an all-in-one application that puts valuable medical information, via your mobile device or the web, in the hands of clinicians treating infants, children, and adolescents. Explore these free sample topics:
-- The first section of this topic is shown below --
INDICATIONS
FDA
FDA
- Before pulled from the U.S. market for hepatotoxicity reasons, the use of trovafloxacin was reserved for use only if the patient meets all of the following criteria:
- Has at least one of the following infections that is judged by the treating physician to be serious and life- or limb-threatening:
- Nosocomial pneumonia
- Community acquired pneumonia
- Complicated intra-abdominal
- Gynecologic, pelvic and skin infections
- Receives initial therapy in an in-patient heath care facility (i.e., hospital or long-term nursing care facility).
- The treating physician believes that, even given the new safety information, the benefit of the product for the patient outweighs the potential risk.
- Use of trovafloxacin was limited to 14 days or less.
- Has at least one of the following infections that is judged by the treating physician to be serious and life- or limb-threatening:
NON-FDA APPROVED USES
NON-FDA APPROVED USES
-- To view the remaining sections of this topic, please log in or purchase a subscription --
INDICATIONS
FDA
FDA
- Before pulled from the U.S. market for hepatotoxicity reasons, the use of trovafloxacin was reserved for use only if the patient meets all of the following criteria:
- Has at least one of the following infections that is judged by the treating physician to be serious and life- or limb-threatening:
- Nosocomial pneumonia
- Community acquired pneumonia
- Complicated intra-abdominal
- Gynecologic, pelvic and skin infections
- Receives initial therapy in an in-patient heath care facility (i.e., hospital or long-term nursing care facility).
- The treating physician believes that, even given the new safety information, the benefit of the product for the patient outweighs the potential risk.
- Use of trovafloxacin was limited to 14 days or less.
- Has at least one of the following infections that is judged by the treating physician to be serious and life- or limb-threatening:
NON-FDA APPROVED USES
NON-FDA APPROVED USES
There's more to see -- the rest of this topic is available only to subscribers.
Last updated: May 1, 2017
Citation
Avdic, Edina, and Paul A Pham. "Trovafloxacin." Johns Hopkins ABX Guide, The Johns Hopkins University, 2017. Pediatrics Central, peds.unboundmedicine.com/pedscentral/view/Johns_Hopkins_ABX_Guide/540567/all/Trovafloxacin.
Avdic E, Pham PA. Trovafloxacin. Johns Hopkins ABX Guide. The Johns Hopkins University; 2017. https://peds.unboundmedicine.com/pedscentral/view/Johns_Hopkins_ABX_Guide/540567/all/Trovafloxacin. Accessed March 20, 2023.
Avdic, E., & Pham, P. A. (2017). Trovafloxacin. In Johns Hopkins ABX Guide. The Johns Hopkins University. https://peds.unboundmedicine.com/pedscentral/view/Johns_Hopkins_ABX_Guide/540567/all/Trovafloxacin
Avdic E, Pham PA. Trovafloxacin [Internet]. In: Johns Hopkins ABX Guide. The Johns Hopkins University; 2017. [cited 2023 March 20]. Available from: https://peds.unboundmedicine.com/pedscentral/view/Johns_Hopkins_ABX_Guide/540567/all/Trovafloxacin.
* Article titles in AMA citation format should be in sentence-case
TY - ELEC
T1 - Trovafloxacin
ID - 540567
A1 - Avdic,Edina,Pharm.D.
AU - Pham,Paul,Pharm.D.
Y1 - 2017/05/01/
BT - Johns Hopkins ABX Guide
UR - https://peds.unboundmedicine.com/pedscentral/view/Johns_Hopkins_ABX_Guide/540567/all/Trovafloxacin
PB - The Johns Hopkins University
DB - Pediatrics Central
DP - Unbound Medicine
ER -